Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Microsoft stock analysis and talk about the risks and upside potential of MSFT stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
01 May 2026, 22:12 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to do a Microsoft stock analysis and talk about the risks and upside potential of MSFT stock
Source overview

AI-generated source summary

The analysis of Microsoft's (MSFT) Q3 FY26 earnings report reveals strong performance metrics. Revenue growth was 18% year-over-year, with Azure cloud growth at 39-40%, exceeding analyst expectations. The company's AI initiatives, particularly Copilot, show increasing adoption, reaching 20 million seats. Despite a projected year-over-year decrease in head count for the 2027 calendar year, the company's capital expenditure is expected to rise significantly to $190 billion in 2026, driven by AI demand and infrastructure needs. The valuation model suggests a potential 115% upside based on a 16% EPS growth assumption and a PE ratio of 24, projecting a future share price of $858.45. The current stock price of $407.78 is considered undervalued given these growth prospects.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail